Shield Therapeutics (LON:STX) Share Price Crosses Below 50-Day Moving Average – What’s Next?

Shield Therapeutics plc (LON:STX)’s stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 9.39 and traded as low as GBX 7.50. Shield Therapeutics shares last traded at GBX 7.75, with a volume of 5,318,340 shares traded.

Shield Therapeutics Stock Up 8.7%

The company has a quick ratio of 2.16, a current ratio of 0.83 and a debt-to-equity ratio of -182.06. The company has a market capitalization of £91.74 million, a P/E ratio of -4.30 and a beta of 1.91. The company has a 50-day moving average of GBX 9.39 and a two-hundred day moving average of GBX 9.04.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.